Future options with trastuzumab for primary systemic and adjuvant therapy

José Baselga, Luca Gianni, Charles Geyer, Edith A. Perez, Alessandro Riva, Christian Jackisch

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

HER2 positivity can be detected early in breast cancer development and is associated with a poor outcome. Primary systemic therapy with trastuzumab (Herceptin; F. Hoffmann-La Roche, Basel, Switzerland) in combination with taxanes and other cytotoxic agents has been studied in phase II clinical trials in women with HER2-positive breast cancer. These combinations have achieved pathologic complete response rates of 12% to 42% and clinical complete response rates of 30% to 67%. These results compare favorably with those of primary systemic therapy using standard combinations in patients with unselected (HER2-positive or -negative) breast cancer. Consequently, larger studies are in progress in which trastuzumab is administered before surgery in combination with chemotherapy. Trastuzumab is continued as monotherapy afterward to complete 1 year of treatment or until disease progression. These studies aim to provide further proof of the clinical benefits associated with trastuzumab as primary systemic therapy. They will also investigate the molecular determinants of sensitivity and resistance. In addition, four major randomized trials, in more than 13,500 patients, are investigating the impact of adding trastuzumab to standard adjuvant therapy. Planned interim cardiac safety analyses have been passed without concerns. Recruitment to these studies has either recently been completed or continues as planned. Together, this extensive program, which includes analysis of predictive molecular and pathologic makers, will establish the efficacy, safety, and role of trastuzumab in early breast cancer.

Original languageEnglish (US)
Pages (from-to)51-57
Number of pages7
JournalSeminars in Oncology
Volume31
Issue numberSUPPL. 10
DOIs
StatePublished - Oct 2004

Fingerprint

Breast Neoplasms
Therapeutics
Safety
Taxoids
Phase II Clinical Trials
Cytotoxins
Trastuzumab
Combination Drug Therapy
Switzerland
Disease Progression

ASJC Scopus subject areas

  • Oncology

Cite this

Baselga, J., Gianni, L., Geyer, C., Perez, E. A., Riva, A., & Jackisch, C. (2004). Future options with trastuzumab for primary systemic and adjuvant therapy. Seminars in Oncology, 31(SUPPL. 10), 51-57. https://doi.org/10.1053/j.seminoncol.2004.07.022

Future options with trastuzumab for primary systemic and adjuvant therapy. / Baselga, José; Gianni, Luca; Geyer, Charles; Perez, Edith A.; Riva, Alessandro; Jackisch, Christian.

In: Seminars in Oncology, Vol. 31, No. SUPPL. 10, 10.2004, p. 51-57.

Research output: Contribution to journalArticle

Baselga, J, Gianni, L, Geyer, C, Perez, EA, Riva, A & Jackisch, C 2004, 'Future options with trastuzumab for primary systemic and adjuvant therapy', Seminars in Oncology, vol. 31, no. SUPPL. 10, pp. 51-57. https://doi.org/10.1053/j.seminoncol.2004.07.022
Baselga J, Gianni L, Geyer C, Perez EA, Riva A, Jackisch C. Future options with trastuzumab for primary systemic and adjuvant therapy. Seminars in Oncology. 2004 Oct;31(SUPPL. 10):51-57. https://doi.org/10.1053/j.seminoncol.2004.07.022
Baselga, José ; Gianni, Luca ; Geyer, Charles ; Perez, Edith A. ; Riva, Alessandro ; Jackisch, Christian. / Future options with trastuzumab for primary systemic and adjuvant therapy. In: Seminars in Oncology. 2004 ; Vol. 31, No. SUPPL. 10. pp. 51-57.
@article{1d99407dbb204adabfad833baf57d07c,
title = "Future options with trastuzumab for primary systemic and adjuvant therapy",
abstract = "HER2 positivity can be detected early in breast cancer development and is associated with a poor outcome. Primary systemic therapy with trastuzumab (Herceptin; F. Hoffmann-La Roche, Basel, Switzerland) in combination with taxanes and other cytotoxic agents has been studied in phase II clinical trials in women with HER2-positive breast cancer. These combinations have achieved pathologic complete response rates of 12{\%} to 42{\%} and clinical complete response rates of 30{\%} to 67{\%}. These results compare favorably with those of primary systemic therapy using standard combinations in patients with unselected (HER2-positive or -negative) breast cancer. Consequently, larger studies are in progress in which trastuzumab is administered before surgery in combination with chemotherapy. Trastuzumab is continued as monotherapy afterward to complete 1 year of treatment or until disease progression. These studies aim to provide further proof of the clinical benefits associated with trastuzumab as primary systemic therapy. They will also investigate the molecular determinants of sensitivity and resistance. In addition, four major randomized trials, in more than 13,500 patients, are investigating the impact of adding trastuzumab to standard adjuvant therapy. Planned interim cardiac safety analyses have been passed without concerns. Recruitment to these studies has either recently been completed or continues as planned. Together, this extensive program, which includes analysis of predictive molecular and pathologic makers, will establish the efficacy, safety, and role of trastuzumab in early breast cancer.",
author = "Jos{\'e} Baselga and Luca Gianni and Charles Geyer and Perez, {Edith A.} and Alessandro Riva and Christian Jackisch",
year = "2004",
month = "10",
doi = "10.1053/j.seminoncol.2004.07.022",
language = "English (US)",
volume = "31",
pages = "51--57",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 10",

}

TY - JOUR

T1 - Future options with trastuzumab for primary systemic and adjuvant therapy

AU - Baselga, José

AU - Gianni, Luca

AU - Geyer, Charles

AU - Perez, Edith A.

AU - Riva, Alessandro

AU - Jackisch, Christian

PY - 2004/10

Y1 - 2004/10

N2 - HER2 positivity can be detected early in breast cancer development and is associated with a poor outcome. Primary systemic therapy with trastuzumab (Herceptin; F. Hoffmann-La Roche, Basel, Switzerland) in combination with taxanes and other cytotoxic agents has been studied in phase II clinical trials in women with HER2-positive breast cancer. These combinations have achieved pathologic complete response rates of 12% to 42% and clinical complete response rates of 30% to 67%. These results compare favorably with those of primary systemic therapy using standard combinations in patients with unselected (HER2-positive or -negative) breast cancer. Consequently, larger studies are in progress in which trastuzumab is administered before surgery in combination with chemotherapy. Trastuzumab is continued as monotherapy afterward to complete 1 year of treatment or until disease progression. These studies aim to provide further proof of the clinical benefits associated with trastuzumab as primary systemic therapy. They will also investigate the molecular determinants of sensitivity and resistance. In addition, four major randomized trials, in more than 13,500 patients, are investigating the impact of adding trastuzumab to standard adjuvant therapy. Planned interim cardiac safety analyses have been passed without concerns. Recruitment to these studies has either recently been completed or continues as planned. Together, this extensive program, which includes analysis of predictive molecular and pathologic makers, will establish the efficacy, safety, and role of trastuzumab in early breast cancer.

AB - HER2 positivity can be detected early in breast cancer development and is associated with a poor outcome. Primary systemic therapy with trastuzumab (Herceptin; F. Hoffmann-La Roche, Basel, Switzerland) in combination with taxanes and other cytotoxic agents has been studied in phase II clinical trials in women with HER2-positive breast cancer. These combinations have achieved pathologic complete response rates of 12% to 42% and clinical complete response rates of 30% to 67%. These results compare favorably with those of primary systemic therapy using standard combinations in patients with unselected (HER2-positive or -negative) breast cancer. Consequently, larger studies are in progress in which trastuzumab is administered before surgery in combination with chemotherapy. Trastuzumab is continued as monotherapy afterward to complete 1 year of treatment or until disease progression. These studies aim to provide further proof of the clinical benefits associated with trastuzumab as primary systemic therapy. They will also investigate the molecular determinants of sensitivity and resistance. In addition, four major randomized trials, in more than 13,500 patients, are investigating the impact of adding trastuzumab to standard adjuvant therapy. Planned interim cardiac safety analyses have been passed without concerns. Recruitment to these studies has either recently been completed or continues as planned. Together, this extensive program, which includes analysis of predictive molecular and pathologic makers, will establish the efficacy, safety, and role of trastuzumab in early breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=5644302245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644302245&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2004.07.022

DO - 10.1053/j.seminoncol.2004.07.022

M3 - Article

C2 - 15490375

AN - SCOPUS:5644302245

VL - 31

SP - 51

EP - 57

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 10

ER -